Why Lilly And Novo Nordisk Will Keep Dominating The Market For Blockbuster GLP-1 DrugsOzempic And Wegovy's Creators Are Likely To Stay On Top. Here's Why - Forbes
forbes.comSubmitted by forbes3707 in health
Despite supply shortages, the GLP-1 drugs by the two companies saw their sales surge in the first quarter of the year, and competitors are still trying to catch up.